<DOC>
	<DOCNO>NCT01189201</DOCNO>
	<brief_summary>The primary objective current study investigate relative bioavailability BI 10773 / linagliptin fix dose combination tablet ( formulation A1 , Treatment A , Test ) compare BI 10773 give free combination linagliptin ( Treatment B , Reference ) , fast state . All 42 subject enter plan include comparison . The secondary objective investigate relative bioavailability BI 10773 / linagliptin fix dose combination tablet administration standardise high fat , high caloric meal ( formulation A1 , Treatment C , Test ) compare BI 10773 / linagliptin fix dose combination fast state ( formulation A1 , Treatment A , Reference ) . Of 42 subject enter 18 subject plan include comparison . An additional objective investigate relative bioavailability second formulation fix dose combination tablet BI 10773 / linagliptin ( formulation A3 , Treatment D , Test ) compare BI 10773 / linagliptin fix dose combination tablet ( formulation A1 , Treatment A , Reference ) . Of 42 subject enter 24 subject plan include comparison .</brief_summary>
	<brief_title>Rel . BA Empagliflozin ( BI 10773 ) /Linagliptin FDC Tbl , Comparison With Mono-components , With Second FDC Tablet Influence Food</brief_title>
	<detailed_description />
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : healthy male female subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>